DKNY1, It is a fact that Adam Feuerstein called for JT to sell AMRN
to BP. Of course, that was before JT expanded the sales force and
did the large offering at $18. Since the Judge Du bombshell hit,
a massive number of AMRN shares have traded at a price of under $8.00.
If BP had any interest in acquiring AMRN when the share price was
over $16, why would't they be more interested with the price now
under $8 and a CEO who is now in a weakened negotiating position?
There is nothing to stop a hostile bid from being made, except for
the prospect of a higher friendly bid. My opinion is Vascepa
will be a more widely used or "optimized" medication if it is
owned by BP. I don't think that is a "conspiracy theory" as
much as it is simple common sense.
The ownership of AMRN may have shifted from what it was before
the Du decision. JT and the BOD should be concerned about who
these new stakeholders are and what they may want.
News 
Market Data 
Discover 
AI
